Shire Pharmaceuticals pretax profits jump 50% as BioChem merger is delayed
Shire Pharmaceuticals of the UK has reported a 31% rise in revenues forfirst-quarter 2001 to $155.6 million, while pretax profits excluding charges climbed 50% to $40.1 million. The revenue increase was driven by the company's amphetamine-based attention-deficit hyperactivity disorder drug Adderall.
The drug brought in $70.1 million, a rise of 29% compared with the like, year-earlier figure and Shire noted that Adderall had a 33.3% share of the ADHD market in the USA by March 2001. Agrylin (anagrelide), which is the only product licensed in the USA for the treatment of thrombocythemia, had sales of $17.1 million, a 56% increase.
Good growth for ProAmatine
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze